Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

doi:10.1016/S0140-6736(16)30169-6

Clinical Trial

. 2016 Aug 6;388(10044):576-85.

doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Harold L Atkins¹, Marjorie Bowman², David Allan³, Grizel Anstee⁴, Douglas L Arnold⁵, Amit Bar-Or⁶, Isabelle Bence-Bruckler⁷, Paul Birch⁸, Christopher Bredeson³, Jacqueline Chen⁹, Dean Fergusson¹⁰, Mike Halpenny⁸, Linda Hamelin⁴, Lothar Huebsch⁷, Brian Hutton¹¹, Pierre Laneuville¹², Yves Lapierre¹³, Hyunwoo Lee¹³, Lisa Martin⁸, Sheryl McDiarmid⁴, Paul O'Connor¹⁴, Timothy Ramsay¹⁰, Mitchell Sabloff⁷, Lisa Walker¹⁵, Mark S Freedman¹⁶

Affiliations

¹ Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada. Electronic address: hatkins@ohri.ca.
² Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.
³ Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁴ The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada.
⁵ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; NeuroRx Research, Montreal, QC, Canada.
⁶ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; Neuroimmunology Unit, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
⁷ The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁸ Ottawa Stem Cell Program, Canadian Blood Services, Ottawa, ON, Canada.
⁹ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; Department of Neurosciences, Cleveland Clinic, Cleveland, OH, USA.
¹⁰ Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
¹¹ Ottawa Hospital Research Institute, Ottawa, ON, Canada.
¹² McGill University Health Center, Montreal, QC, Canada; Division of Oncology, Department of Medicine, McGill University, Montreal, QC, Canada.
¹³ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
¹⁴ Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
¹⁵ School of Psychology, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.
¹⁶ Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.

PMID: 27291994
DOI: 10.1016/S0140-6736(16)30169-6

Clinical Trial

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Harold L Atkins et al. Lancet. 2016.

. 2016 Aug 6;388(10044):576-85.

doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9.

Authors

Affiliations

¹ Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada. Electronic address: hatkins@ohri.ca.
² Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.
³ Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁴ The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada.
⁵ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; NeuroRx Research, Montreal, QC, Canada.
⁶ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; Neuroimmunology Unit, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
⁷ The Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
⁸ Ottawa Stem Cell Program, Canadian Blood Services, Ottawa, ON, Canada.
⁹ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada; Department of Neurosciences, Cleveland Clinic, Cleveland, OH, USA.
¹⁰ Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
¹¹ Ottawa Hospital Research Institute, Ottawa, ON, Canada.
¹² McGill University Health Center, Montreal, QC, Canada; Division of Oncology, Department of Medicine, McGill University, Montreal, QC, Canada.
¹³ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.
¹⁴ Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
¹⁵ School of Psychology, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.
¹⁶ Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Medicine, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital MS Clinic, Ottawa, ON, Canada.

PMID: 27291994
DOI: 10.1016/S0140-6736(16)30169-6

Abstract

Background: Strong immunosuppression, including chemotherapy and immune-depleting antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been used to treat patients with multiple sclerosis, improving control of relapsing disease. We addressed whether near-complete immunoablation followed by immune cell depleted aHSCT would result in long-term control of multiple sclerosis.

Methods: We did this phase 2 single-arm trial at three hospitals in Canada. We enrolled patients with multiple sclerosis, aged 18-50 years with poor prognosis, ongoing disease activity, and an Expanded Disability Status Scale of 3.0-6.0. Autologous CD34 selected haemopoietic stem-cell grafts were collected after mobilisation with cyclophosphamide and filgrastim. Immunoablation with busulfan, cyclophosphamide, and rabbit anti-thymocyte globulin was followed by aHSCT. The primary outcome was multiple sclerosis activity-free survival (events were clinical relapse, appearance of a new or Gd-enhancing lesion on MRI, and sustained progression of Expanded Disability Status Scale score). This study was registered at ClinicalTrials.gov, NCT01099930.

Findings: Between diagnosis and aHSCT, 24 patients had 167 clinical relapses over 140 patient-years with 188 Gd-enhancing lesions on 48 pre-aHSCT MRI scans. Median follow-up was 6.7 years (range 3.9-12.7). The primary outcome, multiple sclerosis activity-free survival at 3 years after transplantation was 69.6% (95% CI 46.6-84.2). With up to 13 years of follow-up after aHSCT, no relapses occurred and no Gd enhancing lesions or new T2 lesions were seen on 314 MRI sequential scans. The rate of brain atrophy decreased to that expected for healthy controls. One of 24 patients died of transplantation-related complications. 35% of patients had a sustained improvement in their Expanded Disability Status Scale score.

Interpretation: We describe the first treatment to fully halt all detectable CNS inflammatory activity in patients with multiple sclerosis for a prolonged period in the absence of any ongoing disease-modifying drugs. Furthermore, many of the patients had substantial recovery of neurological function despite their disease's aggressive nature.

Funding: Multiple Sclerosis Scientific Research Foundation.

Comment in

Haemopoietic stem-cell transplantation for multiple sclerosis: what next?
Dörr J. Dörr J. Lancet. 2016 Aug 6;388(10044):536-8. doi: 10.1016/S0140-6736(16)30377-4. Epub 2016 Jun 9. Lancet. 2016. PMID: 27291993 No abstract available.
Immunoablation and aHSCT for aggressive multiple sclerosis.
Harris M, Cossburn M, Gregory R. Harris M, et al. Lancet. 2017 Mar 4;389(10072):907-908. doi: 10.1016/S0140-6736(17)30605-0. Lancet. 2017. PMID: 28271841 No abstract available.
Immunoablation and aHSCT for aggressive multiple sclerosis - Authors' reply.
Atkins H, Freedman MS. Atkins H, et al. Lancet. 2017 Mar 4;389(10072):908. doi: 10.1016/S0140-6736(17)30592-5. Lancet. 2017. PMID: 28271842 No abstract available.

Cited by

Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis.
Penglase R, Girgis L, Englert H, Brennan X, Jabbour A, Kotlyar E, Ma D, Moore J. Penglase R, et al. J Scleroderma Relat Disord. 2023 Jun;8(2):87-100. doi: 10.1177/23971983221145639. Epub 2023 Feb 7. J Scleroderma Relat Disord. 2023. PMID: 37287946 Review.
Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis.
Kasarełło K, Seta M, Sulejczak D, Snarski E, Cudnoch-Jędrzejewska A. Kasarełło K, et al. Arch Immunol Ther Exp (Warsz). 2023 Mar 24;71(1):10. doi: 10.1007/s00005-023-00675-y. Arch Immunol Ther Exp (Warsz). 2023. PMID: 36964399 Free PMC article.
Augmentation of a neuroprotective myeloid state by hematopoietic cell transplantation.
Mader MM, Napole A, Wu D, Shibuya Y, Scavetti A, Foltz A, Atkins M, Hahn O, Yoo Y, Danziger R, Tan C, Wyss-Coray T, Steinman L, Wernig M. Mader MM, et al. bioRxiv. 2023 Mar 12:2023.03.10.532123. doi: 10.1101/2023.03.10.532123. Preprint. bioRxiv. 2023. PMID: 36945385 Free PMC article.
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G, Signori A, Massacesi L, Mariottini A, Sbragia E, Cottone S, Amato MP, Gasperini C, Moiola L, Meletti S, Repice AM, Brescia Morra V, Salemi G, Patti F, Filippi M, De Luca G, Lus G, Zaffaroni M, Sola P, Conte A, Nistri R, Aguglia U, Granella F, Galgani S, Caniatti LM, Lugaresi A, Romano S, Iaffaldano P, Cocco E, Saccardi R, Angelucci E, Trojano M, Mancardi GL, Sormani MP, Inglese M; Italian BMT-MS Study Group and the Italian MS Register. Boffa G, et al. Neurology. 2023 Mar 14;100(11):e1109-e1122. doi: 10.1212/WNL.0000000000206750. Epub 2022 Dec 21. Neurology. 2023. PMID: 36543569 Free PMC article.
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. Freeman L, et al. CNS Drugs. 2022 Dec;36(12):1285-1299. doi: 10.1007/s40263-022-00965-7. Epub 2022 Nov 9. CNS Drugs. 2022. PMID: 36350491 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Affiliations

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical